Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy
MJ Alberts, J He, A Kharat, V Ashton - American Journal of Cardiovascular …, 2022 - Springer
Background Current evidence suggests that rivaroxaban may be well tolerated and effective
in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited …
in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited …
Comparative effectiveness and safety of rivaroxaban and warfarin among nonvalvular atrial fibrillation (NVAF) patients with obesity and polypharmacy in the United …
JS Berger, F Laliberté, A Kharat, D Lejeune… - Advances in …, 2021 - Springer
Introduction Current evidence indicates that rivaroxaban may be a safe and effective
alternative to warfarin among patients with nonvalvular atrial fibrillation (NVAF) and obesity …
alternative to warfarin among patients with nonvalvular atrial fibrillation (NVAF) and obesity …
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
JS Berger, F Laliberté, A Kharat, D Lejeune… - Current Medical …, 2021 - Taylor & Francis
Objectives Current evidence indicates that the pharmacokinetic profile of rivaroxaban is not
significantly impacted by body weight. However, real-world data are needed to better assess …
significantly impacted by body weight. However, real-world data are needed to better assess …
Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data
OS Costa, J Beyer-Westendorf, V Ashton… - Current Medical …, 2020 - Taylor & Francis
Background: Although rivaroxaban has demonstrated consistent drug levels in normal
weight and obese patients, sufficient confirmation of equal clinical effectiveness and safety is …
weight and obese patients, sufficient confirmation of equal clinical effectiveness and safety is …
[HTML][HTML] Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes
MR Weir, YW Chen, J He, B Bookhart… - Journal of Diabetes and …, 2021 - Elsevier
Aims To compare clinical outcomes of rivaroxaban and warfarin in patients with nonvalvular
atrial fibrillation (NVAF) and concurrent obesity and diabetes. Methods Patients aged≥ 18 …
atrial fibrillation (NVAF) and concurrent obesity and diabetes. Methods Patients aged≥ 18 …
[HTML][HTML] Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
ED Peterson, V Ashton, YW Chen, B Wu… - American heart …, 2019 - Elsevier
Background There are limited data regarding clinical outcomes and healthcare resource
utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are …
utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are …
Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: insights from the ARISTOPHANES study
S Deitelzweig, A Keshishian, A Kang… - Journal of Clinical …, 2020 - mdpi.com
This ARISTOPHANES analysis examined stroke/systemic embolism (SE) and major
bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with …
bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with …
Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2
CP O'Kane, JCO Avalon, JL Lacoste… - … : The Journal of …, 2022 - Wiley Online Library
Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …
[HTML][HTML] Comparative effectiveness and safety of direct oral anticoagulants vs warfarin among obese patients with atrial fibrillation
Background Obese patients are underrepresented in clinical trials assessing the
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Y Murakawa, T Ikeda, S Ogawa, T Kitazono… - Heart and vessels, 2020 - Springer
This sub-analysis of the XAPASS, a prospective, single-arm, observational study, aimed to
evaluate relationships between body mass index (BMI) and safety (major bleeding and all …
evaluate relationships between body mass index (BMI) and safety (major bleeding and all …
相关搜索
- safety of rivaroxaban fibrillation patients
- safety of rivaroxaban obesity and polypharmacy
- obesity and polypharmacy fibrillation patients
- rivaroxaban and warfarin atrial fibrillation
- rivaroxaban and warfarin nvaf patients
- patients with obesity rivaroxaban use
- obese patients warfarin for the management
- japanese patients rivaroxaban treatment
- effectiveness and safety nvaf patients
- effectiveness and safety oral anticoagulants
- effectiveness and safety fibrillation patients
- patients with obesity atrial fibrillation
- obesity and polypharmacy nvaf patients
- safety of rivaroxaban nvaf patients
- obesity and diabetes fibrillation patients
- costs of rivaroxaban atrial fibrillation